COMMUNIQUÉS West-GlobeNewswire

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
11/05/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Cronos Group Reports 2026 First Quarter Results
11/05/2026
Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net [...]
Exagen Inc. Reports First Quarter 2026 Results
11/05/2026
Delivers record total revenue and AVISE(R) CTD average selling price CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported [...]
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA
11/05/2026
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY JUNE 10, 2026, AT 11:00 A.M. – Dear Shareholder, We have the honor of convening you to the Extraordinary General Meeting (the " EGM ") of [...]
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
11/05/2026
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ” ), a clinical-stage biotech [...]
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
11/05/2026
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases
11/05/2026
Collaboration brings AGC Biologics’ advanced therapy expertise and global footprint to OTXL’s network, supporting a sustainable path from clinical development to commercial access for therapies serving the smallest [...]
Cruise Ship Virus Outbreaks Highlight Massive Emerging Demand for TOMI Environmental Solutions’ SteraMist Technology
11/05/2026
Rising Norovirus, Hantavirus, and Pandemic-Era Infection Fears Could Create a Multi-Billion-Dollar Opportunity Across Cruise Ships, Hotels, Hospitals, Airports and Commercial Facilities FREDERICK, Md., May 11, 2026 ( [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
CPTx appoints Edward Rebar as Chief Scientific Officer
11/05/2026
Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform David Maier appointed to expanded role as CPTx Chief Business Officer [...]
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
11/05/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized [...]
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
11/05/2026
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication DMC performed a risk-benefit assessment, identified no new [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA
11/05/2026
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA – MERCREDI 10 JUIN 2026, À 11H00 – Cher Actionnaire, Nous avons l’honneur de vous convoquer à une Assemblée Générale Extraordinaire d’IBA (l’ « AGE » ) au [...]
Leo International Precision Health AG Plans Acquisitions of Nine Additional Assets in Asia and Europe to Accelerate the Commercialization of Its AI-Driven Portfolio Solutions
11/05/2026
Leo International Precision Health AG Plans Acquisitions of Nine Additional Assets in Asia and Europe to Accelerate the Commercialization of Its AI-Driven Portfolio Solutions Expected total transaction volume of EUR 400 [...]
The Next Generation of the GLP-1 Revolution Is Already Underway
11/05/2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of [...]
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
11/05/2026
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
11/05/2026
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to [...]
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
11/05/2026
CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential accelerated drug development WALTHAM, [...]
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
11/05/2026
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 [...]

Pages